ResMed Inc (RMD)
- 31.475
- +0.245+0.78%
ResMed Inc (RMD) 最新新聞
澳大利亞券商電話會議 *特別版* – 2026年8月12日
Jarden重申其對ResMed Inc的買入評級，標的爲每10份普通股對應1份的CHESS存託權益（RMD）
快訊 | ResMed Inc.-受益所有權變動聲明
摩根大通維持對ResMed Inc的買入評級，該股票以每10份CHESS存託權益（CDI）對應1股普通股的比例進行交易（RMD）
根據近期一份美國證券交易委員會（SEC）文件，Resmed內部人士出售了價值$1,026,596的股票。
Michael J. Farrell，董事、董事長兼首席執行官，於2026年8月7日出售了Resmed（RMD）4,991股股票，套現$1,026,596。根據向美國證券交易委員會（SEC）提交的4號表格，Farrell目前持有
ResMed Bull Thinks Five-Year Outlook Is Intact -- Market Talk
0129 GMT - ResMed's bull at Macquarie thinks the breathing-tech provider's five-year outlook remains intact despite its June-quarter gross margin missing expectations. The dual-listed CPAP maker's 4
呼吸機市場到2031年將達到$31億——MarketsandMarkets獨家報告
佛羅里達州德爾雷比奇，2026年8月10日 /PRNewswire/ -- 根據MarketsandMarkets的數據，呼吸機市場預計將從2026年的24.9億增長至2031年的31億，年複合增長率（CAGR）爲4.4%。
Ord Minnett 維持對 ResMed Inc 的買入評級，標的爲其 CHESS 存託權益（CDI），每 10 份 CDI 對應 1 股普通股（RMD）
ResMed Price Target Cut 0.9% to $227.00/Share by Morgan Stanley
ResMed Price Target Cut 0.9% to $227.00/Share by Morgan
花旗維持對ResMed Inc CHESS存託權益（每10份CDI對應1股普通股，代碼RMD）的「持有」評級。
ResMed Price Target Raised 0.4% to A$46.80/Share by Macquarie
ResMed Price Target Raised 0.4% to A$46.80/Share by
ResMed Inc憑藉強勁的核心業務增長抵消了Astral業務的不利影響
分析師就醫療保健公司提供見解：Siemens Healthineers AG（OtherSEMHF）和ResMed Inc以每10份普通股對應1份CDI的比例發行的CHESS存託權益（AU:RMD）
ResMed Inc 每10份普通股對應1份CHESS存託權益（RMD）獲得瑞銀買入評級
ResMed Is Maintained at Neutral by Piper Sandler
ResMed Is Maintained at Neutral by Piper
ResMed Is Maintained at Overweight by Keybanc
ResMed Is Maintained at Overweight by
ResMed Price Target Cut to $255.00/Share From $260.00 by Keybanc
ResMed Price Target Cut to $255.00/Share From $260.00 by
ResMed Is Maintained at Equal-Weight by Wells Fargo
ResMed Is Maintained at Equal-Weight by Wells
ResMed Down Nearly 8%, On Pace For Largest Percent Decrease Since January 2025 -- Data Talk
ResMed Inc. (RMD) is currently at $205.73, down $17.51 or 7.84% --Would be lowest close since July 27, 2026, when it closed at $203.08 --On pace for largest percent decrease since Jan. 31, 2025,
快訊 | ResMed Inc.：瑞穗將目標價從$220上調至$235